SCHEMBL6502748

SCHEMBL6502748

Cc1nc2ccc(C(=O)O)nc2n1Cc1ncc(C(F)(F)F)cc1Cl

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.42
CYP3A4 P08684 2/20 0.42
CYP2D6 P10635 2/20 0.42
CYP2C19 P33261 2/20 0.42
KMT2A Q03164 4/20 0.41
MEN1 O00255 3/20 0.41
NPSR1 Q6W5P4 2/20 0.41
AGBL2 Q5U5Z8 1/20 0.40
GLA P06280 2/20 0.40
CYP2C9 P11712 1/20 0.40
HTT P42858 1/20 0.39
RAB9A P51151 1/20 0.39
ALDH1A1 P00352 2/20 0.39
MRGPRX4 Q96LA9 1/20 0.39
POLB P06746 1/20 0.39
MAPT P10636 1/20 0.39
HPGD P15428 1/20 0.38
KDM4E B2RXH2 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6501965 0.89 CYP1A2 (0.43) CYP1A2CYP3A4CYP2D6CYP2C19KMT2A
SCHEMBL6490587 0.86 SMN1; SMN2 (0.39) KMT2AMEN1ALDH1A1MAPTHPGD
SCHEMBL6493094 0.84 AGBL2 (0.43) CYP1A2CYP3A4CYP2D6CYP2C19KMT2A
SCHEMBL6299386 0.84 MRGPRX4 (0.42) CYP3A4CYP2D6CYP2C19KMT2ACYP2C9
SCHEMBL6135527 0.83 KMT2A (0.46) CYP1A2CYP3A4CYP2D6CYP2C19KMT2A
SCHEMBL6500771 0.81 PPARG (0.48)
SCHEMBL6490770 0.79 P2RX3 (0.39) KMT2AALDH1A1MAPT
SCHEMBL6491410 0.78 ALDH1A1 (0.39) KMT2AMEN1NPSR1HTTRAB9A
SCHEMBL6487805 0.77 KDM4E (0.42) CYP1A2CYP3A4CYP2D6CYP2C19KMT2A
SCHEMBL6491426 0.77 SMN1; SMN2 (0.36) CYP1A2CYP2C19KMT2AMEN1CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6890934-B2 Sulfonamide compounds and uses thereof as medicines FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-05-10 US disclosed
US-20030171396-A1 Sulfonamide compounds and uses thereof as medicines FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2003-09-11 US disclosed
US-6573274-B1 Treatment of the diseases curable based on a hypoglycemic action, and the diseases curable based on a cGMP-PDE inhibitory action, a smooth muscle relaxing action, a bronchodilating action, a vasodilating action, a smooth muscle FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2003-06-03 US disclosed
EP-1136492-A1 SULFONAMIDE COMPOUNDS AND USES THEREOF AS MEDICINES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-09-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030171396-A1 Sulfonamide compounds and uses thereof as medicines PDE2A, PDE3A, PDE5A CYP1A2 1033/4885CYP3A4 1384/4885CYP2D6 1009/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.